Japan

On Phenotype and Function

Deeply profile T cell checkpoint response with mass cytometry immuno-oncology panels

特集

Maxpar Human Immuno-Oncology EX Panel Kits

Designed for multiple product configurations, the Maxpar T Cell Immuno-Oncology Panel grants flexibility to choose complete coverage when combined with other T cell panels, or to customize with individually selected markers of interest.

  • Maximize data collected from limited oncology samples.
  • Investigate T cell activity across all major subtypes at every stage of cancer treatment.
  • Monitor checkpoint expression on T cells in response to treatment and correlate with outcome.
  • Phenotype tumor infiltrates or other tissues, in addition to blood.

The promising field of immuno-oncology presents many unanswered questions for scientists in biopharma, cancer research, flow and mass cytometry core facilities and immunology and immuno-oncology academic institutions: How do cancer cells evade the immune system? Which cells and pathways are the best molecular targets? What is the mechanism of action for potential pharmaceuticals? How can we increase tumor immunogenicity? Which biomarkers could predict response? Which drugs offer the best treatment outcomes, and in what order of use?

Approaches based on immunotherapy are providing unprecedented benefits for cancer patients—most importantly, durable responses and complete remission at rates that far surpass conventional chemotherapy. The defining feature of immunotherapy is that T cells and other cell types in the immune system mediate the anticancer response. But immune system cells also promote adverse reactions in some immunotherapy patients. Monitoring T cells and other immune cells in these patients is important for drug development, understanding mechanisms of action and determining biomarkers that correlate with both response and adverse events.

“Enabling the immune system to recognize and eliminate tumors has tremendous potential to change the way cancer is treated and eventually cured. Using the unique power of mass cytometry, the immuno-oncology research community can identify new biomarkers and optimize the development of new cancer immunotherapies to fully realize the potential of this transformative approach to cancer care.”
—Chris Linthwaite, President and CEO, Fluidigm

The Maxpar® Human T Cell Immuno-Oncology EX Panel Kit—together with the Human T Cell Phenotyping Panel Kits—enables comprehensive identification of all major T cell subsets for determining activation, homing status and checkpoint molecule expression. Designed for use with mass cytometry, with capabilities for measuring more than 40 parameters per cell with little or no signal overlap, these panels reveal highly valuable information from even the most limited biological samples.

Modular configuration makes it easy to combine T Cell Phenotyping Panel Kits for flexible or complete coverage. Individual antibodies offer further customization for specific research needs. With access to a growing catalog of more than 600 commercially available preconjugated antibodies and custom conjugation options, the Maxpar panel system can be adapted to meet changing needs in cancer immunotherapy research.

A new industry standard

“The dynamic nature and inherent complexity of the antitumor immune response requires new approaches to deeply profile cell populations at single-cell resolution,” said Fluidigm President and CEO Chris Linthwaite. “This new set of multiparameter panels will empower more researchers with high-dimensional tools to interrogate the tumor immune response and the tumor microenvironment, maximizing the information obtained from each precious sample.”

“Enabling the immune system to recognize and eliminate tumors has tremendous potential to change the way cancer is treated and eventually cured,” Linthwaite added. “Using the unique power of mass cytometry, the immuno-oncology research community can identify new biomarkers and optimize the development of new cancer immunotherapies to fully realize the potential of this transformative approach to cancer care.”

Mass cytometry is fast becoming an industry standard for deep cellular profiling in translational and clinical research. Referenced by hundreds of peer reviewed publications, mass cytometry expands beyond the inherent technical limitations of flow cytometry. With minimal spectral overlap, the technology enables researchers to interrogate more than 40 parameters simultaneously from millions of cells across both intracellular and extracellular protein markers.

Sample case study

As an example, The Journal of Immunology published a paper by Rituparna Das et al., “Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo,” demonstrating highly multiplexed phenotyping of circulating immune cells to characterize immune response to individual and combination therapies. The report detailed the team’s experimental approach in a 45-patient cancer study at Yale University and Memorial Sloan Kettering Cancer Center.

Das and her collaborators used mass cytometry to perform multiparameter immunophenotyping of human PBMCs from patients before and after they were administered anti-PD-1 and/or anti-CTLA-4 checkpoint blockade therapy. Their customized 20-marker panel included the 16-marker Maxpar Human T Cell Phenotyping Panel Kit. They reported that the population of Ki-67+ cells increasing after anti-CTLA-4 or combination checkpoint blockade had a phenotype of CD45RO+, CCR7−, CD27+, CD28+ and CD95+, “consistent with transitional memory T cells.” These same proliferating cells also upregulated MHC class II HLA-DR.

Such deep profiling and identification of changes in this unique cell population would have been difficult using traditional approaches. Our new T cell immuno-oncology panel sets offer even deeper profiling than those used in the study cited above. Combining Maxpar T cell and immuno-oncology panels creates an unprecedented tool for profiling T cells. These panel sets also illustrate the power of mass cytometry as the premier platform for immune profiling and monitoring applications in translational and clinical research.

Register for the 6th Annual Mass Cytometry Summit in Boston on June 9 to learn about recent insights made using mass cytometry and the Maxpar Human T Cell Immuno-Oncology EX Panel Kit.

fluidigm

For Research Use Only. Not for use in diagnostic procedures.